sales@towardshealthcare.com
+1 804-441-9344
January 2026
The global brain cancer market size was estimated at USD 3.09 billion in 2025 and is predicted to increase from USD 3.4 billion in 2026 to approximately USD 8.06 billion by 2035, expanding at a CAGR of 10.07% from 2026 to 2035.
The brain cancer market is growing due to a growing population with stressful life conditions, a wrong diet, and a busy lifestyle.
| Key Elements | Scope |
| Market Size in 2026 | USD 3.4 Billion |
| Projected Market Size in 2035 | USD 8.06 Billion |
| CAGR (2026 - 2035) | 10.07% |
| Leading Region | North America |
| Market Segmentation | Roche Holding AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca PLC |
| Top Key Players | By Product/Solution Type, By Treatment Modality, By Diagnosis & Monitoring Technology, By End User, By Region |
The brain cancer market involves a multidisciplinary strategy, significantly using surgery, radiation therapy, and chemotherapy, often integrated with novel strategies such as targeted therapy, immunotherapy, and tumor treating fields (TTFields). People who have been exposed to a strong type of radiation called ionizing radiation have an increased risk of brain tumors. Patients with an increased risk of brain tumors may consider screening tests. Brain tumors occur in nerves, the pituitary gland, and the pineal gland.
| Cancer Cases | No. of Cases |
| Estimated New Cases in 2025 | 24,820 |
| Estimated Deaths in 2025 | 18,330 |
The integration of AI-driven technology into brain cancer drives the growth of the market, as AI-driven technology brought transformative innovations to brain tumor management, using imaging, histopathological, and genomic devices for effective identification, categorization, outcome prediction, and treatment planning. AI-driven models efficiently impact various stages of the diagnostic and therapeutic process.
Personalized cancer vaccines have high specificity and work by provoking an immune response directly against cancer cells, thereby reducing the destruction of healthy tissue and lowering off-target effects.
Antibody drug conjugated nanoparticles allow the selective targeting of brain tumor cells by exploiting surface receptors that are overexpressed both on tumor cells and on the endothelial cells of the blood–brain barrier (BBB), transferrin receptor (TfR), and epidermal growth factor receptor (EGFR).
Effectiveness of IDH inhibitors in managing tumors with IDH mutations is superior to that of conventional healthcare therapy, potentially offering more healthcare benefits to patients.
Which Product/Solution Type Led the Brain Cancer Market in 2025?
In 2025, the therapeutic treatments segment held the dominant market share, as these therapies supports treat brain cancer in children. It supports managing cancers that are close to significant parts of the brain. This treatment shrinks the tumor or slows down its growth, which helps people live longer and helps with symptoms. Immunotherapy provides promising choices for managing brain cancer, which is traditionally treated with chemotherapy, radiation therapy, and surgery.
Diagnostic Imaging
Whereas the diagnostic imaging segment is the fastest-growing in the market, as these well-developed imaging processes have shown some promise in differentiating PsP from true tumor reappearance in recurrent cancer. Its capability to produce detailed images of the brain, differentiate cancer types, and guide treatment makes it a significant tool in modern oncology and neurology.
Why did the Chemotherapy Segment Dominate the Market in 2025?
The chemotherapy segment is dominant in the brain cancer market in 2025, as chemotherapy is highly efficient in supervising the growth and spread of brain cancer. It works by inhibiting the division of quickly multiplying tumor cells, therefore lowering cancer size and preventing further progression. Oncologists employ many chemotherapy medicines to target brain tumours. Based on the type of cancer, location, and grade, these medicine be used alone or in combination form.
Immunotherapy
Whereas the immunotherapy segment is the fastest growing in the market, as it is novel and advancing brain cancer immunotherapies have the strength to lower the challenging effects and enhance survival rates for patients with brain cancer. Immunotherapy strengthens or reprograms the body's natural immune response to target and eradicate tumor cells. Immunotherapy has evolved as a promising approches for tackle the brain metastases.
Why did the MRI & CT Imaging Segment Dominate the Market in 2025?
The MRI & CT Imaging segment is dominant in the brain cancer market in 2025, as this type of imaging plays a significant role in the management of patients with brain cancer. The technical advancement of computed tomography (CT) and magnetic resonance (MRI), with the development of novel imaging processes, strongly enhanced the identification and characterization of brain cancer.
PET Imaging
Whereas the PET imaging segment is the fastest growing in the market, as this is a functional imaging technology that plays an increasingly significant role in the management of brain cancer. Positron emission tomography (PET) scans identify early symptoms of cancer, heart disease, and brain conditions. It includes an injection of a safe radioactive tracer that helps detect diseased cells.
Why did the Hospitals Segment Dominate the Market in 2025?
The hospitals segment is dominant in the brain cancer market in 2025, as some kinds of brain cancer, like meningioma, ependymoma, and oligodendroglioma, are extremely treatable. In a hospital treating brain cancer, choices include palliative surgery to lower mass effect, high-dose radiation treatment, chemotherapy, and evolving immunotherapy.
Specialty Cancer Centers
Whereas the specialty cancer centers segment is the fastest growing in the market, as specialty cancer centers manage brain cancer with targeted, multidisciplinary strategies, significantly using surgery such as craniotomy, minimally invasive to get rid of tumors, followed by advanced radiation therapy like Gamma Knife, and Proton Therapy for remaining cells, and then chemotherapy.
In 2025, North America led the brain cancer market, as advancements in scanning and diagnostic technology and changes in environmental challenging factors, the incidence of brain and CNS cancers is expected to grow. Adults aged more than 65 are a fast-growing segment of America's population, who are more prone to brain cancer. Recent research indicates that there is a potential link between moderate to severe traumatic brain injury and a future risk of brain cancer.
U.S. Market Trends
Brain cancer makes up around 1% of the every year cancer diagnoses in the US, affecting the psychological, physical, and cognitive health of the U.S. population. In 2025, 2,041,910 novel cancer cases and 618,120 cancer deaths are estimated to occur in the United States.
Asia Pacific is set to experience rapid growth in the brain cancer market, as significant increase in brain tumor incidence rates both in males and females in this area. Chronic illness integrated with functional damage often results in an increased requirement for health care and supportive long-term care (LTC) solutions. An aging population with the rising challenges of patients with chronic conditions in Asia needs effective health systems with integrated care.
India Market Trends
In India, every fourth person over 60 years and every fifth Indian over 45 years is diagnosed with poor health. India's cancer challenges are growing more rapidly than the worldwide average. Due to the poor healthcare technology in rural regions, lifestyle and environmental factors, and late identification, which drives the growth of the market is expected to grow.
Europe is experiencing substantial growth in the brain cancer market, as brain and CNS cancers are the most common solid cancers in children and adolescents, posing a significant challenge to life quality and expectancy. Cancer care investing has increased in Europe over the past period, significantly because of the increasing number of cancer patients and spending in novel technology, which drives the growth of the market.
UK Market Trends
In the UK, brain cancer, like most other cancers, becomes more common as people age. Each year in the UK, about 13,000 people are diagnosed with a brain cancer. There are around 5,500 deaths because of brain cancer each year in the UK, more than 100 deaths each week. Developments in low-dose CT, MRI, and molecular imaging have recently made it possible to identify cancer earlier, with greater accuracy and lower challenges.
| Company | Headquarters | Latest Update |
| Roche Holding AG | Switzerland | Roche prolonged its healthcare research program with novel trials examining personalized treatments for glioblastoma, one of the most aggressive forms of brain cancer. |
| Novartis AG | Switzerland | Novartis is reimagining cancer care with RLT for patients with advanced cancers |
| Pfizer Inc. | United States | Pfizer is committed to generating a pipeline of novel cancer medicines, treatments, and clinical trials that enhance the outlook for cancer patients globally |
| Merck & Co., Inc. | United States | In June 2025, Merck announced the presentation of novel oncology information across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO). |
| Bristol-Myers Squibb | United States | Bristol Myers Squibb provides brain cancer resources for patients and caregivers, involving data related to brain tumor management. |
| AstraZeneca PLC | Finland | AstraZeneca develops its ambition to redefine haematology care with novel information from its various pipelines. |
By Product/Solution Type
By Treatment Modality
By Diagnosis & Monitoring Technology
By End User
By Region
January 2026
January 2026
January 2026
January 2026